OTCM
AXRX
Market cap16kUSD
Jun 06, Last price
0.00USD
Name
Amexdrug Corp
Chart & Performance
Profile
Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products. It is also involved in the research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices. The company operates in two segments, Distribution and Health and Beauty Products. In addition, it engages in the distribution of prescription and over-the-counter drugs, non-drug products, and health and beauty products; and private manufacturing and labeling activities. Further, the company manufactures and sells facial and body creams, arthritic pain relief medications, and hair and nail care products to pharmacies, beauty salons, beauty supply stores, and other fine shops. Amexdrug Corporation markets its products under the Sponix name. The company distributes its products through its subsidiaries primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities, and other wholesalers and retailers in the state of California. The company was formerly known as Harlyn Products, Inc. and changed its name to Amexdrug Corporation in April 2000 to reflect the change in its business to the sale of pharmaceutical products. Amexdrug Corporation was founded in 1963 and is based in Commerce, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY |
---|---|
2023‑12 | |
Income | |
Revenues | 3,915 |
Cost of revenue | 2,880 |
Unusual Expense (Income) | |
NOPBT | 1,035 |
NOPBT Margin | 26.43% |
Operating Taxes | (168) |
Tax Rate | |
NOPAT | 1,203 |
Net income | 36 |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
Debt | |
Debt current | 1 |
Long-term debt | 490 |
Deferred revenue | |
Other long-term liabilities | |
Net debt | (821) |
Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
Balance | |
Cash | 1,313 |
Long term investments | |
Excess cash | 1,117 |
Stockholders' equity | 1,753 |
Invested Capital | 1,128 |
ROIC | 106.67% |
ROCE | 46.11% |
EV | |
Common stock shares outstanding | 169,410 |
Price | |
Market cap | |
EV | |
EBITDA | 1,035 |
EV/EBITDA | |
Interest | 81 |
Interest/NOPBT | 7.85% |